trending Market Intelligence /marketintelligence/en/news-insights/trending/-YvkIfsgRrb0j0-ql_uU7A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Recipharm to acquire Sanofi's UK-based inhalation contract business for £45M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Recipharm to acquire Sanofi's UK-based inhalation contract business for £45M

Sweden's Recipharm AB said it will acquire Sanofi's contract inhalation drug business in the U.K. for about £45 million.

The French drugmaker has a facility based in Holmes Chapel near Manchester that employs about 450 people and is involved in manufacturing metered-dose inhalers and nasal sprays for respiratory diseases.

The business generated about £51 million in revenues during the 12 months ended March.

Recipharm, which provides contract development and manufacturing solutions, said the acquisition will add to its inhalation drug product manufacturing capabilities in the U.S. and allow it to take advantage of the growing respiratory drug market, specifically for chronic obstructive pulmonary disease and asthma.

Sanofi has also entered a long-term supply agreement with Recipharm for the products manufactured at the facility.

Recipharm, which previously acquired a Spain-based manufacturing facility from Roche Holding AG, said it may also pay up to £9 million in 2020 and 2021 if the newly purchased business meets certain goals.

The Sweden-based company said the transaction is expected to be accretive to EBITDA-margin and EPS from the first quarter of 2019.